Supporting Filings for CRISPR Genome-Edited CAR-T Cell Therapies
Customer Testimonial from Caribou Biosciences
"Solvias’ Targeted Locus Amplification (TLA) assay, developed by Cergentis, has been important for ensuring our allogeneic CAR-T cell therapies meet the stringent criteria for use in patients. TLA provides on-target, off-target, and structural variant information which have supported our filings with the U.S. FDA for our three clinical-stage programs, CB-010, CB-011, and CB-012. The Solvias team’s expertise in genomic characterization has helped us establish the assays needed for each of our CRISPR genome-edited CART cell therapies."
Scott Gradia, PhD
Vice President of Platform Research at Caribou Biosciences
Discover how we empower clients like Caribou. Download our sample report now!
Our Collaboration
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing. They use their novel, next generation CRISPR genome-editing technology to armor allogeneic, or off-the-shelf, CAR-T cell therapies for potentially improved antitumor activity.
Solvias (initially Cergentis) has worked closely with Caribou for 5 years, supporting the quality control of their CAR-T cells targeting hematologic malignancies ahead of regulatory filings and for use in patients. Specifically, Solvias’ Targeted Locus Amplification (TLA) assay, developed by Cergentis, has been used as part of the quality control process for Caribou's product candidates to help characterize the precision of genome edits, including gene knockouts and transgene insertions.
We are proud to support Caribou’s work as they advance their mission to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing.